All In Biotech

Drug Trial Radar · NCT07008378

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Aug 31, 2032

Study completion Aug 31, 2032

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Poseida Therapeutics, Inc., a member of the Roche Group
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

Conditions

  • Multiple Sclerosis

Interventions

  • P-CD19CD20-ALLO1 CellsBiological

    P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered intravenously.

  • FludarabineDrug

    Fludarabine will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1Time frame: Day 1 up to Day 29
  2. Number of Participants With Adverse Events (AEs)Time frame: Up to 5 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UCSD Altman Clinical and Translational Research Institute

    La Jolla, California

  • Washington University School of Medicine

    St Louis, Missouri

  • Rutgers University- Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Multiple Sclerosis Comprehensive Care Center at Northwell Health

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.